Compare Li Auto Inc (LI) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Natera Inc. Common Stock — how do they compare? Li Auto Inc trades at $11.27 (market cap $11.27B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 5.1× Li Auto Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Li Auto Inc for 102 Days and Natera Inc. Common Stock for 0 Days on average.
| LI | NTRA | |
|---|---|---|
Market Cap | $11.27B | $57.03B |
Volume | 3,921,121 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.72 | $425.64 |
52-Week Low | $10.69 | $179.42 |
Typical Hold Time | 102 Days | 0 Days |
Enterprise Value | $673.48M | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $11.26, down 1.23% on the day and near its 52-week low, reflecting bearish technical signals and recent delivery declines. The company reported revenue of $112.31B in 2025 with a net income of $1.12B, but profitability metrics like net income margin and ROE remain negative. Recent news highlights challenges in China's EV market, with September 2026 deliveries of 31,817 vehicles showing moderation. Analyst consensus is mixed, with a $15.18 price target suggesting potential upside from current levels.
The outlook for LI is cautious due to intense competition and cash flow pressures, with net cash flow negative $9.0B in 2025. Investment opportunities include new model launches like the Li i9 SUV and global expansion, but risks from market volatility and execution missteps persist. Investors should weigh the company's solid balance sheet against near-term headwinds.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
